A group intervention which assists patients with dual diagnosis reduce their drug use: A randomized controlled trial

Psychological Medicine

Volumn 34, Issue 6, 2004, Pages 983-990

  James, W ^a,b,c   Preston, N J ^a,b,c   Koh, G ^a,b,c   Spencer, C ^a,b,c   Kisely, S R ^a,b,c   Castle, David J ^a,b,c  

^a FREMANTLE HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; CANNABIS; CHLORPROMAZINE; COCAINE; DIAMORPHINE; ILLICIT DRUG; NEUROLEPTIC AGENT; PSYCHEDELIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DEPENDENCE; FEMALE; FOLLOW UP; GROUP THERAPY; HEROIN DEPENDENCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTIVATION; PATIENT EDUCATION; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ADULT; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; MALE; PSYCHOTHERAPY, GROUP; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 4444254146     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0033291703001648     Document Type: Article

References (36)

1. Abramson, J. H. & Gahlinger, P. M. (2001). Computer Programs for Epidemiologists: PEPI version 4. Sagebrush Press: Salt Lake City, Utah, USA [www.sagebrushpress.com/pepibook.html].
2. Addington, J. & Duchak, V. (1997). Reasons for substance use in schizophrenia. Acta Psychiatrica Scandinavica 96, 329-333.
3. Baigent, M., Holme, G. & Hafner, R. J. (1995). Self-reports of the interaction between substance abuse and schizophrenia. Australian and New Zealand Journal of Psychiatry 29, 69-74.
4. Barrowclough, C., Haddock, G., Tarrier, N., Lewis, S., Moring, J., O'Brien, R., Schofield, N. & McGovern, J. (2001). Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with co-morbid schizophrenia and substance use disorders. American Journal of Psychiatry 158, 1706-1713.
5. Bond, G. R., McDonel, E. C., Miller, L. D. & Pensec, M. (1991). Assertive community treatment and reference groups: an evaluation of their effectiveness for young adults with serious mental illness and substance abuse problems. Psychosocial Rehabilitation Journal 15, 31-43.
6. British Medical Association (2002). British National Formulary. BMJ Books: London.
7. Darke, S., Hall, W., Wodak, A., Heather, N. & Ward, J. (1992). Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. British Journal of Addiction 87, 733-742.
8. Dawe, S., Loxton, N., Hides, L., Kavanagh, D. & Mattick, R. P. (2002). Review of Diagnostic Screening Instruments for Alcohol and Other Drug Use and Other Psychiatric Disorders (2nd edn). Australian Government Publishing Service: Canberra [http://www.health.gov.au/pubhlth/publicat/document/mono48.pdf].
9. Dawe, S. & Mattick, R. P. (1997). Review of Diagnostic Screening Instruments for Alcohol and Other Drug Use and Other Psychiatric Disorders. Australian Government Publishing Service: Canberra.
10. Department of Health (2002). Mental Health Policy Implementation Guide: Dual Diagnosis Good Practice Guide. Department of Health Publications: London.
11. Derogatis, L. R. (1993). BSI: Brief Symptom Inventory. National Computer Systems: Minneapolis.
12. Dixon, L. (1999). Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research 35, 93-100.
13. Dixon, L., Haas, G., Weiden, P. J., Sweeney, J. & Frances, A. J. (1991). Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry 148, 224.
14. Drake, R. E., Mercer-McFadden, C., Mueser, K. T., McHugo, G. J. & Bond, G. R. (1998). Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophrenia Bulletin 24, 589-608.
15. Drake, R. E. & Mueser, K. T. (2000). Psychosocial approaches to dual diagnosis. Schizophrenia Bulletin 26, 105-118.
16. Fowler, I. L., Carr, V. J., Carter, N. T. & Lewin, T. J. (1998). Patterns of current and lifetime substance abuse in schizophrenia. Schizophrenia Bulletin 24, 443-445.
17. Gavin, D. R., Ross, H. E. & Skinner, H. A. (1989). Diagnostic validity of the Drug Abuse Screening Test in the assessment of DSM-III drug disorders. British Journal of Addiction 84, 301-307.
18. Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W. & Strang, J. (1995). The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90, 607-614.
19. James, W. & Castle, D. (2003). Substance abuse co-morbidity in schizophrenia. In Pharmacological and Psychosocial Treatments for Schizophrenia (ed. D. J. Castle. D. Copolov and T. Wykes), pp. 75-87. Martin Dunitz: London.
20. James, W., Koh, G., Spencer, C., Preston, N., Kisely, S. & Castle, D. (2002). Managing Mental Health & Drug Use. Uniprint: Perth, Western Australia.
21. Krausz, M., Haasen, C., Mass, R., Wagner, H. B., Peter, H. & Freyberger, H. S. (1996). Harmful use of psychotropic substances by schizophrenics: coincidence, patterns of use and motivation. European Addiction Research 2, 11-16.
22. Ley, A., McLaren, S. & Siegfried, N. (2001). Treatment programmes for people with both severe mental illness and substance misuse (Cochrane Review). Cochrane Library. Issue 1.
23. Martinez-Aravelo, M. J., Calcedo-Ordonez, A. & Varo-Prieto, J. R. (1994). Cannabis consumption as a prognostic factor in schizophrenia. British Journal of Psychiatry 164, 679-681.
24. McGuffin, P., Farmer, A. & Harvey, I. (1991). A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Archives of General Psychiatry 48, 764-770.
25. Mueser, K. T., Nishith, P., Tracy, J. L., DeGirolamo, L. & Molinaro, M. (1995). Expectations and motives for substance use in schizophrenia. Schizophrenia Bulletin 21, 367-378.
26. Overall, J. E. & Gorham, D. R. (1962). The brief psychiatric rating scale. Psychological Reports 10, 799-812.
27. Prochasca, J. & DiClemente, C. (1986). Toward a comprehensive model of change. In Treating Addictive Behaviours. Process of Change (ed. L. D. Miller & N. Heather), pp. 3-27. Plenum: New York.
28. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L. & Goodwin, F. K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association 264, 2511-2518.
29. Schneier, F. R. & Siris, S. G. (1987). A review of psychoactive substance abuse and schizophrenia: patterns of drug choice. Journal of Nervous and Mental Disease 175, 641-652.
30. Siegfried, N. (1998). A review of comorbidity: major mental illness and problematic Substance use. Australian and New Zealand Journal of Psychiatry 32, 707-717.
31. Spencer, C., Castle, D. & Michie, P. (2002). An examination of the validity of a motivational model for understanding substance use among individuals with psychotic disorders. Schizophrenia Research 28, 233-247.
32. Strakowski, S. M., McElroy, S. L., Keck, P. W. & Wesy, S. A. (1994). The co-occurrence of mania with medical and other psychiatric disorders. International Journal of Psychiatry Medicine 22, 305-328.
33. Skinner, H. A. (1982). The drug abuse screening test. Addictive Behaviours 7, 363-371.
34. Test, M. A., Wallisch, L. S., Allness, D. J. & Ripp, K. (1989). Substance abuse in young adults with schizophrenic disorders. Schizophrenia Bulletin 15, 465-476.
35. Warner, M. B., Taylor, D., Wright, J., Sloat, A., Springet, G., Arnold, S. & Weinberg, H. (1994). Substance use among the mentally ill: prevalence, reasons for use and effects on illness. American Journal of Orthopsychiatry 64, 30-39.
36. WHO (1994). The ICD-10 Classification of Mental and Behavioural Disorders. World Health Organisation: Geneva.